|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1991-10-24
|
|
pubmed:abstractText |
We have determined the percentage of CD5+ B lymphocytes in the peripheral blood of cancer patients and healthy controls, using antibodies directed at the CD5 and CD19 (pan-B) markers. The frequencies of CD5+ B cells, expressed as a percentage of total B cells, ranged from 14.3 to 57.5% in the controls and from 14.8 to 82.8% in the patient population. One-third of the cancer patients had frequencies greater than 2 s.d. above the mean of the control population. The CD5+ B cell fraction expressed as a percentage of total lymphocytes was also significantly elevated in this group of cancer patients. These results suggest that the CD5+ B cell compartment may be affected by the malignant process or by the therapy modality employed. The plasma levels of several naturally occurring autoantibodies, the products of the CD5+ B cells, were also assessed in cancer patients and controls. No significant differences were observed when reactivity to several autoantigens was measured. These included nuclear components and phospholipids.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2465285,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2467934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2479233,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2480138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2482031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2646863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2785560,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-2953812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3050475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3073176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3073177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3096879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3147270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3169848,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3225188,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3288167,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3335005,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3488968,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-3683415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-6804567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1716541-7046921
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
418-23
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1716541-Adolescent,
pubmed-meshheading:1716541-Adult,
pubmed-meshheading:1716541-Aged,
pubmed-meshheading:1716541-Aged, 80 and over,
pubmed-meshheading:1716541-Antigens, CD,
pubmed-meshheading:1716541-Antigens, CD5,
pubmed-meshheading:1716541-Autoantibodies,
pubmed-meshheading:1716541-B-Lymphocyte Subsets,
pubmed-meshheading:1716541-B-Lymphocytes,
pubmed-meshheading:1716541-Child,
pubmed-meshheading:1716541-Child, Preschool,
pubmed-meshheading:1716541-Female,
pubmed-meshheading:1716541-Humans,
pubmed-meshheading:1716541-Male,
pubmed-meshheading:1716541-Middle Aged,
pubmed-meshheading:1716541-Neoplasms
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
CD5+ B cells and naturally occurring autoantibodies in cancer patients.
|
|
pubmed:affiliation |
Garden State Cancer Center, Newark, NJ 07103.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
